Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs Group

Seres Therapeutics (NASDAQ:MCRB) had its price objective lowered by analysts at The Goldman Sachs Group from $1.00 to $0.75 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “sell” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target suggests a potential upside of 8.85% from the company’s previous close.

MCRB has been the topic of a number of other research reports. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Seres Therapeutics presently has an average rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Stock Up 7.9 %

MCRB stock traded up $0.05 during mid-day trading on Friday, hitting $0.69. 546,700 shares of the company were exchanged, compared to its average volume of 1,389,521. The firm has a market capitalization of $119.96 million, a P/E ratio of -3.00 and a beta of 2.19. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.83. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $1.53.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Millennium Management LLC boosted its position in shares of Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock worth $1,505,000 after purchasing an additional 788,762 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 37,866 shares in the last quarter. Northern Trust Corp boosted its position in shares of Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 44,461 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after purchasing an additional 121,793 shares in the last quarter. Finally, Avantax Advisory Services Inc. boosted its position in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.